Workflow
Olivier Clovis Scaling Business Launches Sales Funnel Coaching Program to Help Entrepreneurs Scale Online Businesses
GlobeNewswire News Room· 2025-09-03 21:00
Geneva, Switzerland , Sept. 03, 2025 (GLOBE NEWSWIRE) -- Olivier Clovis Scaling Business, a Swiss-based coaching and digital strategy company, announced today the launch of a specialized sales funnel coaching program designed to help entrepreneurs scale their online businesses. The program, developed by founder and sales funnel expert Olivier Clovis, introduces a proven customer journey model that guides low-ticket buyers toward high-ticket offers—helping business owners recoup ad spend early, increase clie ...
Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client Next Technology Holding Inc. (NASDAQ: NXTT)
Newsfilter· 2025-09-03 21:00
New York, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the "Offering") for its client Next Technology Holding Inc. (NASDAQ: NXTT) (the "Company"), a technology company built on a dual-engine strategy of "AI plus digital assets." Under the terms of the securities purchase agreement, the Company has agreed to s ...
Alphabet: Strong Tailwind For Cloud If The New Siri Uses Gemini As A Base Model
Seeking Alpha· 2025-09-03 20:59
Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...
Altai Announces Shareholder Approval of Special Resolution
Globenewswire· 2025-09-03 20:59
TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Altai Resources Inc. (TSXV: ATI) (“Altai” or the “Company”) announced that at today’s special meeting (the “Meeting”) of shareholders of the Company (the “Shareholders”), the Shareholders approved, with approximately 96.4% of the votes cast in favor of, a special resolution (the “Stated Capital Reduction Resolution”) authorizing and approving a reduction of the stated capital account of the common shares of the Company (the “Common Shares”) by an aggregate amount ...
Alnylam Pharmaceuticals, Inc. (ALNY) Presents At Citi's Biopharma Back To School Conference Prepared Remarks Transcript
Seeking Alpha· 2025-09-03 20:58
PresentationThank you all. Welcome all again to the 2025 Citi Biopharma Conference in Boston. Next on the docket, we have Alnylam. If you could, I guess, introduce us and kind of tell us a little bit about the company for no one who's -- for people who haven't heard of you before, bring us up to speed, that would be great.Jeffrey PoultonCFO & Executive VP [indiscernible] very productive organic platform for the company. We've got 6 products in the market today, 4 of which that we're marketing ourselves, whi ...
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
Globenewswire· 2025-09-03 20:57
Core Insights - vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes treatment [1][2] - The company will participate in two upcoming investor conferences in September 2025, including the H.C. Wainwright 27th Annual Global Investment Conference and the Morgan Stanley 23rd Annual Global Healthcare Conference [1][2] Company Overview - vTv Therapeutics specializes in oral, small molecule drug candidates aimed at treating diabetes and other chronic diseases [2] - The clinical pipeline is led by cadisegliatin, which is currently in a Phase 3 trial as a potential oral glucokinase activator for type 1 diabetes [2] - The company is also exploring multiple molecules across various indications for chronic diseases in collaboration with development partners [2]
C3 AI reports declining revenue, announces new CEO to replace Siebel
CNBC· 2025-09-03 20:55
The C3.ai logo is seen near a computer motherboard in this illustration taken on Jan. 8, 2024.Shares of the enterprise artificial intelligence company C3 AI fell 14% in extended trading on Wednesday after it announced fiscal first-quarter results and the appointment of Stephen Ehikian as its new CEO.C3 AI reported $70.3 million in revenue for the quarter, down from $87.2 million during the same period last year. The company's GAAP net loss widened to an 86-cent loss from a 50-cent loss a year ago.Ehikian is ...
DexCom, Inc. (DXCM) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Seeking Alpha· 2025-09-03 20:53
Core Insights - The discussion features management from DexCom, including the newly appointed CEO Jake Leach and CFO Jereme Sylvain [1] Company Overview - Jake Leach has been promoted to CEO, effective January 1, 2026, marking his first fireside chat in this new role [1]
Lowe's Companies, Inc. (LOW) Presents At Goldman Sachs 32nd Annual Global Retailing Conference 2025 Transcript
Seeking Alpha· 2025-09-03 20:53
PresentationI am going to turn the podium over to Marvin for some prepared comments. We're doing this one a little bit differently as my questions are going to be non-deal-related topics. And with that, I will turn it over to Marvin.Good afternoon, everyone. Thank you. It's my pleasure to introduce the management for Lowe's. Today, we have with us Marvin Ellison, Chairman, President and Chief Executive Officer. Marvin was appointed in his current role in 2018 and has more than 30 years of leadership and ope ...
ChargePoint Stock Slides After Q2 Results: Here's Why
Benzinga· 2025-09-03 20:52
Core Insights - ChargePoint Holdings, Inc. reported a quarterly loss of $1.42 per share, which was worse than the analyst estimate of a loss of $1.21 [1] - The company's quarterly revenue was $98.59 million, exceeding the Street estimate of $96.64 million [1] Financial Performance - ChargePoint's networked charging systems revenue for the first quarter was $50.4 million, a decrease of 21% from $64.1 million in the same quarter of the previous year [4] - Subscription revenue increased to $39.9 million, up 10% from $36.2 million in the prior year's same quarter [4] - Non-GAAP gross margin improved to 33%, compared to 26% in the prior year's same quarter, primarily due to growth in subscription revenue [4] - Non-GAAP operating expenses were $58.6 million, down 12% from $66.4 million in the prior year's same quarter [4] Future Outlook - ChargePoint anticipates third-quarter revenue to be in the range of $90 million to $100 million, lower than the analyst estimate of $106.69 million [3] - Following the earnings report, ChargePoint's stock price fell by 4.92% to $10.25 in extended trading [3] Management Commentary - CEO Rick Wilmer highlighted that the focus on operational excellence has led to improvements in gross margin and cash management, and the commitment to innovation is resulting in new products that are positively received in the market [2]